Discounted Cash Flow (DCF) Analysis Unlevered

Relay Therapeutics, Inc. (RLAY)

$18.58

+0.31 (+1.70%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 18.58 | undervalue

Operating Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ---------
Revenue (%)
EBITDA ---------
EBITDA (%)
EBIT ---------
EBIT (%)
Depreciation ---------
Depreciation (%)

Balance Sheet Data

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ---------
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories ---------
Inventories (%)
Accounts Payable ---------
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 18.58
Beta 1.028
Diluted Shares Outstanding 42.62
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 8.554
Total Debt 22.90
Total Equity 791.87
Total Capital 814.77
Debt Weighting 2.81
Equity Weighting 97.19
Wacc

Build Up Free Cash

Year
A/P
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ---------
EBITDA ---------
EBIT ---------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT ---------
Depreciation ---------
Accounts Receivable ---------
Inventories ---------
Accounts Payable ---------
Capital Expenditure -1.69-8-1.93-3.47-----
UFCF ---------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -257.22
Equity Value -
Shares Outstanding 42.62
Equity Value Per Share -